The Research Value of Multi-omics and Multi-modal Information in the Diagnosis and Treatment of Urinary System Tumors

Launched by UNION HOSPITAL, TONGJI MEDICAL COLLEGE, HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY · Jun 30, 2024

Keywords

ClinConnect Summary

This clinical trial is investigating how different types of information can help doctors diagnose and treat cancers in the urinary system, such as bladder, kidney, and prostate cancer. Researchers will collect tissue samples from patients and analyze them using advanced techniques to understand the tumors better. This study aims to find new ways to improve treatment and care for people with these types of cancer.

To participate, you need to be at least 18 years old and have been treated for bladder, kidney, or prostate cancer at Wuhan Union Hospital between January 2024 and January 2026. If you have had tests that suggest you have one of these cancers and a biopsy has confirmed it, you may be eligible. During the trial, participants can expect to provide tumor samples and undergo various tests to help researchers gather valuable information. It's important to note that patients with other types of cancer or unclear diagnoses will not be included in the study.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Patients were treated for bladder cancer, kidney cancer, and prostate cancer in Wuhan Union Hospital from January 2024 to January 2026;
• • 2. Aged \> 18 years old;
• • 3. Urinalysis, urine exfoliated cells, ultrasound, CT, and MR examinations indicated the above tumors;
• • 4. Tissue biopsy pathological examination confirmed the diagnosis of the above tumors.
• Exclusion Criteria:
• • 1. Poor image quality;
• • 2. Incomplete clinical data or loss of follow-up;
• • 3. Presence of another primary malignant tumor other than urinary tract tumor;
• • 4. Unclear pathological diagnosis